Serina Therapeutics (SER) Proxy filing summary

Executive summary

• Annual Meeting scheduled for December 13, 2024, to be held virtually with no in-person attendance.

• Key items for shareholder vote include director elections, auditor ratification, and an amendment to the 2024 Equity Incentive Plan.

• Board recommends voting in favor of all proposals presented.

• Proxy materials and annual report are available online for shareholder review.

Voting matters and shareholder proposals

• Election of three Class I directors (Balkrishan “Simba” Gill, Remy Gross, Steven Mintz) for terms expiring at the 2027 Annual Meeting.

• Ratification of Frazier & Deeter, LLC as independent registered public accountants for fiscal year ending December 31, 2024.

• Approval of an amendment to the 2024 Equity Incentive Plan to increase share reserve to 2,675,000, add an evergreen provision, and modify share reversion provisions.

• Shareholders may submit proposals for the 2025 Annual Meeting by July 4, 2025, for inclusion in the proxy statement.

Board of directors and corporate governance

• Board is divided into three classes with staggered three-year terms; current nominees are all incumbents.

• Board leadership is separated between Chair (Dr. Gill) and CEO (Mr. Ledger) to reinforce independence.

• All directors except the CEO are considered independent under NYSE American standards.

• Committees include Audit, Compensation, Nominating and Corporate Governance, and Science and Technology.

• Code of Ethics applies to all directors and executive officers, with disclosures of amendments or waivers made on the company website.